NDA

Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update

Retrieved on: 
Thursday, August 25, 2022
Biotechnology, Pharmaceutical, Health, Neurology, Inflammation, Partnership, COVID-19, TBI, NDA, Tablet, Research, Technology, Second, Survival, Amyotrophic lateral sclerosis, Central nervous system, Spinal muscular atrophy, Cognition, Toxicity, Disease, Burn, R, Gemstone, USD, Depreciation, Advertising, ACOG, TSX, Alzheimer's disease, Growth hacking, Rivastigmine, OTC Markets Group, Neurodegeneration, Donepezil, Company, FDA, Memantine, Met, News, Failure, Transaction, TSX Venture Exchange, Terminology, Potential, Growth, Industry, Discovery, Acquisition, Capsule, ALS, Patient, P-value, Income, Pharmaceutical industry, Renewable energy, Medical device, Dietary supplement, Online gambling, Cryptocurrency, Tutoring, G&A

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results and provided a corporate update for the second quarter ended June 30, 2022.

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results and provided a corporate update for the second quarter ended June 30, 2022.
  • "The Company released positive topline data from the ALPHA-1062 pivotal trial during the second quarter of 2022 which allows for the preparation of an NDA filing for the product.
  • The Company is seeking additional capital to fund this study initiation and will commence the study within a quarter to securing the required funding.
  • R&D expenses increased in 2022 primarily due to the additional costs associated with advancing ALPHA-1062 and ALPHA-0602 clinical and preclinical studies.

Global Female Infertility Drug Pipeline Market Report 2022: Insights about 12 Pipelines Drugs Including Emerging Drugs - OXO-001 (Oxolife) & Nolasiban (ObsEva) - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Health, Pharmaceutical, NDA, Technology, II, Safety, Human, Research, Embryo transfer, Reproductive medicine, Endometrium, Infertility, Ovulation, PCOS, Fertility, Therapy, News, ART, Clinical trial, Woman, Acquisition, Discovery, Pregnancy, Patient, Birth control, Pharmaceutical industry, Female infertility, Female

The "Global Female Infertility - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Female Infertility - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Female Infertility - Pipeline Insight, 2022" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Female Infertility pipeline landscape.
  • A detailed picture of the Female Infertility pipeline landscape is provided which includes the disease overview and Female Infertility treatment guidelines.
  • The assessment part of the report embraces, in depth Female Infertility commercial assessment and clinical assessment of the pipeline products under development.

Global Acute Ischemic Stroke Drug Pipeline Market Research 2022: Comprehensive Insights About 35+ Companies and 35+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Neurology, Stem Cells, Pharmaceutical, Managed Care, Health, Medical Devices, Genetics, Clinical Trials, Mortality, Threonine, AIS, Tenecteplase, Ministry, NDA, Technology, Human, Safety, Plasmin, Clinical trial, Tissue plasminogen activator, TPA, Glutamine, Death, Bleeding, Cerebral infarction, Half-life, Antioxidant, Stroke, Organic acid, Disability, Fibrin, Therapy, Edema, News, III, TNK, Asparagine, Acquisition, Discovery, Oxidative stress, Ministry of Health and Welfare (Taiwan), NMDA, Patient, Dietary supplement, Pharmaceutical industry, Health

This "Acute Ischemic Stroke - Pipeline Insight, 2022" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Acute Ischemic Stroke pipeline landscape.

Key Points: 
  • This "Acute Ischemic Stroke - Pipeline Insight, 2022" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Acute Ischemic Stroke pipeline landscape.
  • A detailed picture of the Acute Ischemic Stroke pipeline landscape is provided which includes the disease overview and Acute Ischemic Stroke treatment guidelines.
  • The assessment part of the report embraces, in depth Acute Ischemic Stroke commercial assessment and clinical assessment of the pipeline products under development.
  • The companies which have their Acute Ischemic Stroke drug candidates in the most advanced stage, i.e.

Global ANCA Vasculitis Drug Pipeline Market Research Report 2022 Featuring GSK, AstraZeneca, Staidson Biopharmaceuticals, Bristol-Myers Squibb, InflaRx, Chia Tai Tianqing Pharmaceutical & Visterra - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Health, Pharmaceutical, AstraZeneca, Eosinophilic granulomatosis with polyangiitis, NDA, II, Technology, Benralizumab, Asthma, Survival, Awareness, Macrophage, Disease, Signal transduction, Basophil, Vasculitis, MedImmune, GlaxoSmithKline, ANCA, FDA, Therapy, Eosinophil, News, III, Clinical trial, Immunoglobulin G, Microscopic polyangiitis, Acquisition, Discovery, Patient, Pharmaceutical industry

The "Global ANCA Vasculitis - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global ANCA Vasculitis - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "ANCA Vasculitis - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in ANCA Vasculitis pipeline landscape.
  • A detailed picture of the ANCA Vasculitis pipeline landscape is provided which includes the disease overview and ANCA Vasculitis treatment guidelines.
  • The assessment part of the report embraces, in depth ANCA Vasculitis commercial assessment and clinical assessment of the pipeline products under development.

Global IgA Nephropathy (IgAN) Drug Market Research Report 2022: Pipeline Analysis, Therapeutic Assessment, Unmet Needs, Impact of Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Health, Pharmaceutical, NDA, Technology, II, Immunoglobulin A, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Administration, Route of administration, New Drug Application, Glomerulonephritis, Food, Kidney disease, Route, FDA, News, III, Clinical trial, Acquisition, Discovery, Patient, Medical device, Pharmaceutical industry, Atrasentan, IgA nephropathy

This "IgA Nephropathy - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape.

Key Points: 
  • This "IgA Nephropathy - Pipeline Insight, 2022" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape.
  • A detailed picture of the IgA Nephropathy pipeline landscape is provided which includes the disease overview and IgA Nephropathy treatment guidelines.
  • The assessment part of the report embraces, in depth IgA Nephropathy commercial assessment and clinical assessment of the pipeline products under development.
  • IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Hypoparathyroidism Drug Pipeline Market Analysis 2022 Featuring Ascendis, Calcilytix Therapeutics, Amolyt, AEterna Zentaris, Entera Bio, Sigilon Therapeutics, ProLynx, & Extend Biosciences - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Health, Pharmaceutical, NDA, Technology, Administration, Route of administration, Serum, Southern Transcon, Quality of life, Calcium, Route, Parathyroid hormone, News, III, PTH, Clinical trial, Calcium-sensing receptor, Acquisition, Discovery, Medical device, Pharmaceutical industry, Hypoparathyroidism

This "Hypoparathyroidism - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hypoparathyroidism pipeline landscape.

Key Points: 
  • This "Hypoparathyroidism - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hypoparathyroidism pipeline landscape.
  • A detailed picture of the Hypoparathyroidism pipeline landscape is provided which includes the disease overview and Hypoparathyroidism treatment guidelines.
  • The assessment part of the report embraces, in depth Hypoparathyroidism commercial assessment and clinical assessment of the pipeline products under development.
  • Hypoparathyroidism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – TGTX

Retrieved on: 
Wednesday, August 24, 2022
Ext, Lists of action films, NDA, BLA, Securities Exchange Act of 1934, TG, SEC Rule 10b-5, Survival, Degenerative disease, District court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Follicular lymphoma, NASDAQ, LLP, Lists of schools in England, Oncology Drug Advisory Committee, Death, Multiple sclerosis, Chronic lymphocytic leukemia, Person, New Drug Application, Overalls, Food, Court, CLL, Complaint, Lymphoid leukemia, GLOBE, Company, FDA, News, ODAC, Adult, Biologics license application, SLL, Pomerantz, Risk, Shanda, Prescription Drug User Fee Act, Acquisition, Review, Patient, Medical device, Pharmaceutical industry, High-performance plastics, Umbralisib, Ublituximab, U2

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • TG Therapeutics, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SmileDirectClub Partners With The National Dental Association To Offer Scholarships To Dental Students and Professionals of Color

Retrieved on: 
Wednesday, August 24, 2022
Partnership, National Dental Association, Workforce, Research, NDA, Health equity, Dentistry, Education, Dental care, Student, GLOBE, Population, Color, SmileDirectClub, Mentorship, Marketing, Industry, Dentist, Love, Health insurance

Research has shown there is a correlation between the lack of dentists of color and inequality in dental care.

Key Points: 
  • Research has shown there is a correlation between the lack of dentists of color and inequality in dental care.
  • Applications for the SmileDirectClub Scholarship are now open through Sept. 26 for second, third, and fourth-year students studying dentistry and post-graduate students studying public health/policy.
  • The National Dental Association is pleased to once again partner with SmileDirectClub to offer a scholarship program for dental students that will alleviate their student debt burden.
  • Eliminating some financial stressors will empower dental students and professionals and open doors of possibilities for career advancement in the dental industry, said Dr. Cheryl Lee, President of the National Dental Association.

Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies

Retrieved on: 
Wednesday, August 24, 2022
Safety, Chemistry, Food and Drug Administration, Integrity, Toxicity, R & D, Interleukin 2, CD4, PD-1, Company, MD Anderson Cancer Center, Social conditions in Honduras, Patient, Cancer, Food, Senior, CMC, Sintilimab, Lymphoma, HKEX, Trial of the century, NDA, R, NMPA, Adalimumab, Immunotherapy, Stock exchange, News, Eli Lilly and Company, Marketing, Nature, Control, Ophthalmology, Motherboard, IND, HK, Autoimmunity, Bevacizumab, CD8, Eli Lilly, Innovation Academy Charter School, Clinical trial, Environment, Pharmaceutical industry, Vaccine, Fine chemical, Ramucirumab, Regulatory T cell, Spotlight Innovation, Incyte

Dr. Hui Zhou, Senior Vice President of Innovent,stated:"Most patients will develop primary or secondary resistance after treatments of immune checkpoint inhibitors.

Key Points: 
  • Dr. Hui Zhou, Senior Vice President of Innovent,stated:"Most patients will develop primary or secondary resistance after treatments of immune checkpoint inhibitors.
  • We are looking forward to the positive results of IBI363 in patients with advanced solid tumors or lymphoma.
  • IBI363 is our first molecule to initiate clinical study in Australia, which marks a solid step of Innovent's global innovation strategy.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

TG Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; Deadline September 16, 2022; the Portnoy Law Firm

Retrieved on: 
Tuesday, August 23, 2022
NDA, TG, Survival, Therapy, NASDAQ, Lists of schools in England, Overalls, Complaint, GLOBE, Company, FDA, U2, Review, Pharmaceutical industry, Umbralisib, Ublituximab

LOS ANGELES, Aug. 23, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) investors that a class action filed on behalf of investors. TG Therapeutics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, Aug. 23, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises TG Therapeutics, Inc. (TG Therapeutics or the Company) (NASDAQ: TGTX) investors that a class action filed on behalf of investors.
  • TG Therapeutics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.